Literature DB >> 29334181

Donor Variability in Growth Kinetics of Healthy hMSCs Using Manual Processing: Considerations for Manufacture of Cell Therapies.

Giulia Detela1, Owen W Bain1, Hae-Won Kim2,3, David J Williams4, Chris Mason1, Anthony Mathur5, Ivan B Wall1,2,6.   

Abstract

Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell therapy but their expansion to desired clinical quantities can be compromised by ex vivo processing, due to differences between donor material and process variation. The aim of this article is to characterize growth kinetics of healthy baseline "reference" hMSCs using typical manual processing. Bone-marrow derived hMSCs from ten donors are isolated based on plastic adherence, expanded, and analyzed for their growth kinetics until passage 4. Results indicate that hMSC density decreases with overall time in culture (p < 0.001) but no significant differences are observed between successive passages after passage 1. In addition, fold increase in cell number dropped between passage 1 and 2 for three batches, which correlated to lower performance in total fold increase and expansion potential of these batches, suggesting that proliferative ability of hMSCs can be predicted at an early stage. An indicative bounded operating window is determined between passage 1 and 3 (PDL < 10), despite the high inter-donor variability present under standardized hMSC expansion conditions used. hMSC growth profile analysis will be of benefit to cell therapy manufacturing as a tool to predict culture performance and attainment of clinically-relevant yields, therefore stratifying the patient population based on early observation.
© 2018 The Authors. Biotechnology Journal Published by WILEY-VCH Verlag GmbH & Co. KGaA.

Entities:  

Keywords:  autologous cell therapies; bioprocess design; expansion potential; human mesenchymal stromal cells (hMSCs); variability

Mesh:

Substances:

Year:  2018        PMID: 29334181     DOI: 10.1002/biot.201700085

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  6 in total

1.  In vitro induction of quiescence in isolated primary human myoblasts.

Authors:  Kirankumar B Gudagudi; Niccolò Passerin d'Entrèves; Nicholas J Woudberg; Paul J Steyn; Kathryn H Myburgh
Journal:  Cytotechnology       Date:  2020-01-28       Impact factor: 2.058

2.  Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

Authors:  David F Stroncek; Ping Jin; David H McKenna; Minoko Takanashi; Magali J Fontaine; Shibani Pati; Richard Schäfer; Emily Peterson; Eric Benedetti; Jo-Anna Reems
Journal:  Front Cell Dev Biol       Date:  2020-06-16

Review 3.  Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine.

Authors:  Alison Wilson; Andrew Webster; Paul Genever
Journal:  Regen Med       Date:  2019-05-22       Impact factor: 3.806

4.  The Impact of Various Culture Conditions on Human Mesenchymal Stromal Cells Metabolism.

Authors:  Pavla Tonarova; Katerina Lochovska; Robert Pytlik; Marie Hubalek Kalbacova
Journal:  Stem Cells Int       Date:  2021-03-01       Impact factor: 5.443

5.  In-situ scalable manufacturing of Epstein-Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA).

Authors:  Sixun Chen; Ahmad Amirul Bin Abdul Rahim; Who-Whong Wang; Rachael Cheong; Akshaya V Prabhu; Jerome Zu Yao Tan; May Win Naing; Han Chong Toh; Dan Liu
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

6.  Donor genetic backgrounds contribute to the functional heterogeneity of stem cells and clinical outcomes.

Authors:  Ting Wang; Juan Zhang; Jinqi Liao; Fan Zhang; Guangqian Zhou
Journal:  Stem Cells Transl Med       Date:  2020-08-24       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.